Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PTGIR | P43119 | 5/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5141951 | 0.86 | DRD2 (0.60) | DRD2LMNAPRMT5WDR77DRD3 | |
| SCHEMBL5142060 | 0.85 | ADRB3 (0.48) | PRMT5WDR77POLBNPSR1ADRB3 | |
| SCHEMBL7562058 | 0.85 | ADRB3 (0.44) | DRD2PRMT5WDR77DRD3POLB | |
| Hydrochloric Acid SCHEMBL7565474 | 0.84 | ADRB3 (0.47) | PRMT5WDR77POLBNPSR1ADRB3 | |
| SCHEMBL7570285 | 0.81 | NPSR1 (0.48) | DRD2LMNAPRMT5WDR77DRD3 | |
| SCHEMBL7570358 | 0.80 | MEN1 (0.52) | LMNAPOLBADRB3 | |
| SCHEMBL5146452 | 0.79 | PRMT5 (0.48) | DRD2LMNAPRMT5WDR77POLB | |
| Hydrochloric Acid SCHEMBL7566243 | 0.79 | MEN1 (0.51) | LMNAPOLBADRB3 | |
| Hydrochloric Acid SCHEMBL5145557 | 0.79 | DRD2 (0.52) | DRD2LMNAPRMT5WDR77POLB | |
| SCHEMBL5143855 | 0.76 | PRMT5 (0.47) | DRD2LMNAPRMT5WDR77POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6391915-B2 | ANTIULCER AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-21 | — | — | US | disclosed |
| US-20020006956-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-17 | — | — | US | disclosed |
| EP-0976720-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006956-A1 | Propanolamine derivatives | PNLIP, ADRB1, FABP2 | DRD2 115/4885LMNA 2259/4885PRMT5 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.